Influence of Cardiometabolic Risk Factors on Platelet Function

• Published in: International journal of molecular sciences Vol. 21; no. 2; p. 623
• Main Authors: Barale, Cristina, Russo, Isabella
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 17.01.2020; MDPI
• Subjects: Abdomen; Blood clots; Blood platelets; Blood pressure; Collagen; Cytokines; Diabetes; Epidemiology; Growth factors; Heart attacks; Insulin resistance; Ischemia; Metabolic syndrome; Obesity; Oxidative stress; Pathogenesis; Physiology; Review; Risk factors; Thrombosis; metabolic syndrome; nitric oxide; thrombosis; adipose tissue; adipokines; hemostasis; insulin resistance; oxidative stress; platelets
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms21020623

Platelets are key players in the thrombotic processes. The alterations of platelet function due to the occurrence of metabolic disorders contribute to an increased trend to thrombus formation and arterial occlusion, thus playing a major role in the increased risk of atherothrombotic events in patients with cardiometabolic risk factors. Several lines of evidence strongly correlate metabolic disorders such as obesity, a classical condition of insulin resistance, dyslipidemia, and impaired glucose homeostasis with cardiovascular diseases. The presence of these clinical features together with hypertension and disturbed microhemorrheology are responsible for the prothrombotic tendency due, at least partially, to platelet hyperaggregability and hyperactivation. A number of clinical platelet markers are elevated in obese and type 2 diabetes (T2DM) patients, including the mean platelet volume, circulating levels of platelet microparticles, oxidation products, platelet-derived soluble P-selectin and CD40L, thus contributing to an intersection between obesity, inflammation, and thrombosis. In subjects with insulin resistance and T2DM some defects depend on a reduced sensitivity to mediators—such as nitric oxide and prostacyclin—playing a physiological role in the control of platelet aggregability. Furthermore, other alterations occur only in relation to hyperglycemia. In this review, the main cardiometabolic risk factors, all components of metabolic syndrome involved in the prothrombotic tendency, will be taken into account considering some of the mechanisms involved in the alterations of platelet function resulting in platelet hyperactivation.